Gastroenteropancreatic tumor

Anthuber M, Jauch KW, Briegel J, et al. (1996) Results of liver transplantation for gastroenteropancreatic tumor metastases. World J Surg 20 73 -76... 

Faiss S, Pape UF, Bohmig M, et al. (2003) Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors—The International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21 2689-2696... 

The expression of neuro D1 and mammalian achaete-scute complex-like protein (MASH) have been assessed in gastroenteropancreatic (GEP) tumors.These studies have demonstrated that MASH-1 is highly expressed in poorly differentiated GEP tumors, whereas neuroDl is present in all well-differentiated carcinomas and tumors. Interestingly, low levels of neuroDl expression were seen in approximately one third of poorly differentiated GEP carcinomas and this feature was associated with a significantly shorter overall survival. 

Kloppel G, Rindi G, Anlauf M, et al. Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors. Virchows Arch. 2007 451(Suppl l) S9-27. 

Nash SV, Said JW. Gastroenteropancreatic neuroendocrine tumors. A histochemical and immunohistochemical study of epithelial (keratin proteins, carcinoembryonic antigen) and neuroendocrine (neuron-specific enolase, bombesin and chromo-granin) markers in foregut, midgut, and hindgut tumors. Am J Clin Pathol. 1986 86 415-422. 

Anlauf M, Garbrecht N, Bauersfeld J, et al. Hereditary neuroendocrine tumors of the gastroenteropancreatic system. Virchows Arch. 2007 451(Suppl 1) S29-S38. 

In a second trial [108], 27 patients with SSR-positive gastroenteropancreatic malignancies who had failed aU other therapies were administered two single doses of 6.7 GBq (180 mGi) of In-DTPA-D-Phe -octreotide. Glinical benefit was achieved in 62% of patients, and tumor-associated pan-creastatin levels decreased significantly in 81%. Objective PRs were obtained in two of 26 (8%) evaluable patients, and com-... 

Furthermore, FDOPA-PET seems to have a promising role in patients with gastroenteropancreatic NET, with negative or inconclusive findings at conventional morphological or conventional SRS (Ambrosini et aL 2007), where it could help to detect the primary tumor or other unsuspected lesions in the majority of patients. 

---